It has been suggested that patients with NAFLD have lower concentrations of biologically active incretin hormones compared to healthy individuals, which may be a consequence of an increased degradation by dipeptidyl peptidase 4 (DPP-4) (the enzyme, which under normal conditions inactivates the incretin hormones) (29) or a decreased production (30, 31). The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.